U.S. Markets closed

Infinity Pharmaceuticals, Inc. (INFI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.1500+0.1600 (+5.35%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.9900
Open3.0200
Bid3.0900 x 3100
Ask3.1900 x 800
Day's Range2.9600 - 3.2000
52 Week Range0.7800 - 5.9800
Volume703,899
Avg. Volume4,125,636
Market Cap279.239M
Beta (5Y Monthly)2.31
PE Ratio (TTM)N/A
EPS (TTM)-0.6760
Earnings DateMay 10, 2021 - May 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
  • Business Wire

    Infinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast

    Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Thursday, May 13th 2021 at 4:30pm ET to report its financial results for the first quarter of 2021.

  • Business Wire

    Infinity to Present at New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021

    Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that the Company will have a presentation summarizing recent eganelisib clinical data will be followed by a Q&A session at the New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021 virtual symposium taking place on May 12-14, 2021.

  • Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks

    Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.